A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma.
Oral idarubicin (40 mg/m2 in 3-4 divided doses over 24 h every 21 days) was tested in a group of patients with drug-resistant ovarian carcinoma. None of 13 patients responded and the study was discontinued. Toxicity was acceptable, with neutropaenia being dose-limiting. It seems unlikely that idarubicin has significant activity in this disease although phase II studies should ideally be conducted in less heavily pretreated patients.
Williams
C J
CJ
CRC Medical Oncology Unit, Southampton General Hospital, U.K.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
D015255:Idarubicin